Rheumatology International

, 29:173

Interleukin-17F gene polymorphisms in Korean patients with Behçet’s disease

  • Won-Cheoul Jang
  • Yun-Hyoung Nam
  • Young-Chang Ahn
  • Sang-Hyun Lee
  • Sung-Hoon Park
  • Jung-Yoon Choe
  • Shin-Seok Lee
  • Seong-Kyu Kim
Original Article

Abstract

IL-17 is a novel cytokine that is characterized by an ability to induce several types of cells to secrete proinflammatory cytokines in various inflammatory diseases. This study analyzed the influence of IL-17F gene polymorphisms on disease susceptibility and clinical features. Ninety-nine Behçet’s disease (BD) patients and 114 controls were genotyped to analyze three single nucleotide polymorphisms (SNPs) including A126G, G155A, and A161G of the IL-17F gene using automated sequencing. We compared the frequencies of IL-17F alleles, genotypes, and haplotypes in patients with BD and controls using the chi-square or Fisher’s exact test. Significant differences in the frequencies of allele and genotype in A126G SNP of IL-17 gene were found between BD patients and controls (P < 0.001 and P < 0.001, respectively). None of three IL-17F SNPs were associated with diverse clinical features in BD. The frequency of haplotype AA did not differ between patients with BD and controls (P = 0.985). The haplotypes, AG, and GG, have positive and inverse association with BD susceptibility (P < 0.001 and P < 0.001, respectively). These findings suggest that IL-17 gene SNPs may influence the susceptibility of BD.

Keywords

IL-17F Polymorphisms Behçet’s disease 

References

  1. 1.
    Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341:1284–1291. doi:10.1056/NEJM199910213411707 PubMedCrossRefGoogle Scholar
  2. 2.
    Fresko I, Soy M, Hamuryudan V, Yurdakul S, Yavuz S, Tumer Z et al (1998) Genetic anticipation in Behcet’s syndrome. Ann Rheum Dis 57:45–48PubMedCrossRefGoogle Scholar
  3. 3.
    Yokota K, Oguma K (1997) IgA protease produced by Streptococcus sanguis and antibody production against IgA protease in patients with Behcet’s disease. Microbiol Immunol 41:925–931PubMedGoogle Scholar
  4. 4.
    Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizoguchi M (1994) Interleukin 8 in Behcet’s disease. J Dermatol 21:397–404PubMedGoogle Scholar
  5. 5.
    Adam B, Calikoglu E (2004) Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behcet’s disease. J Eur Acad Dermatol Venereol 18:318–320. doi:10.1111/j.1468-3083.2004.00907.x PubMedCrossRefGoogle Scholar
  6. 6.
    Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet’s disease. Mediators Inflamm 11:87–93. doi:10.1080/09629350220131935 PubMedCrossRefGoogle Scholar
  7. 7.
    Musabak U, Pay S, Erdem H, Simsek I, Pekel A, Dinc A et al (2006) Serum interleukin-18 levels in patients with Behcet’s disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 26:545–550. doi:10.1007/s00296-005-0029-8 PubMedCrossRefGoogle Scholar
  8. 8.
    Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK (2004) IL-17 cytokine family. J Allergy Clin Immunol 114:1265–1273. doi:10.1016/j.jaci.2004.10.019 PubMedCrossRefGoogle Scholar
  9. 9.
    Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155–174. doi:10.1016/S1359-6101(03)00002-9 PubMedCrossRefGoogle Scholar
  10. 10.
    Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3:168–177. doi:10.1186/ar294 PubMedCrossRefGoogle Scholar
  11. 11.
    Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y et al (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43:2455–2463. doi :10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-KGoogle Scholar
  12. 12.
    Wong CK, Ho CY, Li EK, Lam CW (2000) Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9:589–593. doi:10.1191/096120300678828703 PubMedCrossRefGoogle Scholar
  13. 13.
    Honorati MC, Bovara M, Cattini L, Piacentini A, Facchini A (2002) Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage 10:799–807. doi:10.1053/joca.2002.0829 PubMedCrossRefGoogle Scholar
  14. 14.
    Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Behcet’s disease patients Relationship with disease activity. Scand J Rheumatol 31:205–210. doi:10.1080/030097402320318387 PubMedCrossRefGoogle Scholar
  15. 15.
    International Study Group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080Google Scholar
  16. 16.
    Chang HK, Cheon KS (2002) The clinical significance of a pathergy reaction in patients with Behçet’s disease. J Korean Med Sci 17:371–374PubMedGoogle Scholar
  17. 17.
    Chang HK, Kim JU, Cheon KS, Chung HR, Lee KW, Lee IH (2001) HLA-B51 and its allelic types in association with Behçet’s disease and recurrent aphthous stomatitis in Korea. Clin Exp Rheumatol 19(Suppl 24):S31–S35PubMedGoogle Scholar
  18. 18.
    Jung HY, Park JS, Park YJ, Kim YJ, Kimm K, Koh IS (2004) HapAnalyzer: minimum haplotype analysis system for association studies. Genomics Inf 2:107–109Google Scholar
  19. 19.
    Park K, Kim N, Nam J, Bang D, Lee ES (2006) Association of TNFA promoter region haplotype in Behcet’s disease. J Korean Med Sci 21:596–601. doi:10.3346/jkms.2006.21.4.596 PubMedCrossRefGoogle Scholar
  20. 20.
    Lee EB, Kim JY, Zhao J, Park MH, Song YW (2007) Haplotype association of IL-8 gene with Behcet’s disease. Tissue Antigens 69:128–132. doi:10.1111/j.1399-0039.2006.00736.x PubMedCrossRefGoogle Scholar
  21. 21.
    Jang WC, Park SB, Nam YH, Lee SS, Kim JW, Chang IS et al (2005) Interleukin-18 gene polymorphisms in Korean patients with Behcet’s disease. Clin Exp Rheumatol 23(Suppl 38):S59–S63PubMedGoogle Scholar
  22. 22.
    Chang HK, Jang WC, Park SB, Han SM, Nam YH, Lee SS et al (2005) Association between interleukin 6 gene polymorphisms and Behcet’s disease in Korean people. Ann Rheum Dis 64:339–340. doi:10.1136/ard.2004.024208 PubMedCrossRefGoogle Scholar
  23. 23.
    Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H et al (2008) Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 49:3058–3064. doi:10.1167/iovs.07-1390 PubMedCrossRefGoogle Scholar
  24. 24.
    Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F et al (2006) IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 117:795–801. doi:10.1016/j.jaci.2005.12.1346 PubMedCrossRefGoogle Scholar
  25. 25.
    Southam L, Heath O, Chapman K, Loughlin J (2006) Association analysis of the interleukin 17 genes IL17A and IL17F as potential osteoarthritis susceptibility loci. Ann Rheum Dis 65:556–557. doi:10.1136/ard.2005.045922 PubMedCrossRefGoogle Scholar
  26. 26.
    Ramsey CD, Lazarus R, Camargo CA Jr, Weiss ST, Celedon JC (2005) Polymorphisms in the interleukin 17F gene (IL17F) and asthma. Genes Immun 6:236–241. doi:10.1038/sj.gene.6364170 PubMedCrossRefGoogle Scholar
  27. 27.
    Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM et al (2005) Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123–1132. doi:10.1038/ni1254 PubMedCrossRefGoogle Scholar
  28. 28.
    Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A (2003) IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. Immunol 170:2106–2112Google Scholar
  29. 29.
    Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M et al (2003) Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 111:1293–1298. doi:10.1067/mai.2003.1557 PubMedCrossRefGoogle Scholar
  30. 30.
    Witowski J, Ksiazek K, Jorres A (2004) Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 61:567–579. doi:10.1007/s00018-003-3228-z PubMedCrossRefGoogle Scholar
  31. 31.
    Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P et al (2001) IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 20:5332–5341. doi:10.1093/emboj/20.19.5332 PubMedCrossRefGoogle Scholar
  32. 32.
    Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P (2003) Cytokines and chemokines in neuro-Behcet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 145:127–134. doi:10.1016/j.jneuroim.2003.08.040 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Won-Cheoul Jang
    • 1
  • Yun-Hyoung Nam
    • 1
  • Young-Chang Ahn
    • 1
  • Sang-Hyun Lee
    • 1
  • Sung-Hoon Park
    • 2
  • Jung-Yoon Choe
    • 2
  • Shin-Seok Lee
    • 3
  • Seong-Kyu Kim
    • 2
  1. 1.Department of ChemistrySchool of Advanced Science, Dankook UniversityCheonanSouth Korea
  2. 2.Department of Internal MedicineCatholic University of Daegu School of MedicineDaeguSouth Korea
  3. 3.Department of Internal MedicineChonnam National University Medical SchoolGwangjuSouth Korea

Personalised recommendations